Bayer Should Ax Calcium Supplement Claims: Ad Regulator

Law360, New York (July 12, 2012, 6:46 PM EDT) -- The National Advertising Division recommended Wednesday that Bayer HealthCare AG stop claiming or implying that one dose of its daily calcium supplement provides the same level of calcium as competing products that require two daily doses, saying the claim misleads consumers.

NAD said in a statement that Bayer and its advertisers did not use sufficient or reliable evidence — in particular, the division questioned the use of a pharmacokinetic study — to support its claims when advertising or marketing its Citracal Slow Release 1200.

Launched last...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.